BioCryst Pharmaceuticals
BCRX
8.40
+0.45
+5.66%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
8.40
+0.45
+5.66%
Live - 5344 symbols - heartbeat 552s ago
· 2026-10-08 08:10
Pre-market
8.54
+1.67%
After-hours
8.38
-0.24%
- Market cap
- 2.15B
- P/E (TTM)i
- -6.00
- P/Bi
- -4.72
- EPSi
- 1.21
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on BCRX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
19.57 +133.0%
Price target rangecurrent 8.40
Low11.00
Avg19.57
High32.00
Buy 71%
Hold 29%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | J.P. Morgan | -- | HOLD | 13.00 |
| 2026-09-10 | RBC Capital | -- | HOLD | 11.00 |
| 2026-09-08 | Needham | -- | BUY | 16.00 |
| 2026-08-06 | Wedbush | -- | BUY | 20.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 32.00 |
| 2026-08-05 | TD Cowen | -- | BUY | 30.00 |
| 2026-08-05 | Needham | -- | BUY | 16.00 |
| 2026-08-05 | RBC Capital | -- | BUY | 13.00 |
| 2026-07-15 | BofA Securities | -- | BUY | 15.00 |
| 2026-07-13 | Wedbush | -- | BUY | 21.00 |
| 2026-07-13 | J.P. Morgan | -- | HOLD | 12.00 |
| 2026-07-07 | RBC Capital | -- | BUY | 14.00 |
| 2026-06-30 | Cantor Fitzgerald | -- | BUY | 29.00 |
| 2026-06-30 | Wedbush | -- | BUY | 21.00 |
| 2026-06-30 | Needham | -- | BUY | 16.00 |
| 2026-06-30 | H.C. Wainwright | -- | BUY | 32.00 |
| 2026-06-29 | Needham | -- | BUY | 16.00 |
| 2026-05-07 | Wedbush | -- | BUY | 21.00 |
| 2026-05-07 | Citizens JMP | -- | BUY | 28.00 |
| 2026-05-07 | H.C. Wainwright | -- | BUY | 32.00 |
| 2026-05-06 | TD Cowen | -- | BUY | 30.00 |
| 2026-05-06 | Needham | -- | BUY | 16.00 |
| 2026-05-06 | RBC Capital | -- | BUY | 13.00 |
| 2026-04-16 | BofA Securities | -- | BUY | -- |
| 2026-04-07 | RBC Capital | -- | BUY | 14.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: RBC Capital moved from Buy to Hold on 2026-09-10.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-10 | RBC Capital | BUY → HOLD | 11.00 |
| 2026-02-18 | Evercore | HOLD → BUY | 17.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | -- | ±11.90% | +0.55% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±10.52% | -2.21% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±8.74% | +4.64% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±16.39% | -6.28% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±16.93% | +9.81% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±11.67% | +23.52% (beat) |
| 2024/Q4 | 2025-02-24 | -- | ±15.83% | -9.99% (in line) |
| 2024/Q3 | 2024-11-04 | -- | ±15.08% | -12.81% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±17.02% | +6.98% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±17.53% | +18.43% (beat) |
| 2023/Q4 | 2024-02-26 | -- | ±24.27% | +1.40% (in line) |
| 2023/Q3 | 2023-11-02 | -- | ±16.35% | -1.57% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:10:31 · For reference only, not investment advice and not tailored to your situation.